T86.03
BillableBone marrow transplant infection
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is T86.03 an HCC code?
Yes. T86.03 maps to Graft-Versus-Host Disease and Stem Cell Transplant Complications under the CMS-HCC V28 risk adjustment model (and Major Organ Transplant or Replacement Status under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for T86.03
For T86.03 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed T86.03 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
T86.03 is the ICD-10-CM diagnosis code for bone marrow transplant infection. An infection develops as a complication of bone marrow transplant, often due to the immunosuppressed state of the transplant recipient. T86.03 sits in the ICD-10-CM chapter for injury, poisoning and certain other consequences of external causes (s00-t88), within the section covering complications of surgical and medical care, not elsewhere classified (t80-t88).
Under the CMS-HCC V28 risk adjustment model, T86.03 maps to Graft-Versus-Host Disease and Stem Cell Transplant Complications (HCC 454) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, T86.03 maps to Major Organ Transplant or Replacement Status (HCC 186) with a community, non-dual, aged base RAF weight of 0.910. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Code the specific infectious organism separately if identified (e.g., CMV, fungal infection, bacterial sepsis). Because T86.03 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for T86.03 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Code the specific infectious organism separately if identified (e.g., CMV, fungal infection, bacterial sepsis)
- •Include seventh character for episode of care and ensure the infection code is linked to the transplant complication
Clinical Significance
This represents infection occurring as a complication of bone marrow transplant, often due to the patient's immunosuppressed state and compromised immune function. These infections can be life-threatening and require immediate intervention with antimicrobial therapy, representing a common but serious complication requiring specialized infectious disease management.
Documentation Requirements
- ✓Documentation of infection in transplant recipient
- ✓Type and location of infection
- ✓Causative organism if identified
- ✓Relationship to immunosuppressed state
- ✓Current antimicrobial treatment
- ✓Response to therapy
- ✓Impact on graft function
- ✓Modification of immunosuppressive regimen